Volume : X, Issue : III, March - 2020

A REVIEW ON HEPATOTOXICITY OF ANTITUBERCULOSIS THERAPY

Dr. Siddharth, G. Priyanka, Mirza Hassan

Abstract :

The correlation between serum anti–tuberculosis (TB) drug levels and the drug–induced hepatotoxicity (DIH) remains unclear. The purpose of this study was to investigate whether anti–TB DIH is associated with basal serum drug levels. Serum peak levels of isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA), and ethambutol (EMB) were analyzed in blood samples 2 hr after the administration of anti–TB medication. Anti–TB DIH and mild liver function test abnormality were diagnosed on the basis of laboratory and clinical criteria. Serum anti–TB drug levels and other clinical factors were compared between the hepatotoxicity and non–hepatotoxicity groups. A total of 195 TB patients were included in the study, and the data were analyzed retrospectively. Seventeen (8.7%) of the 195 patients showed hepatotoxicity, and the mean aspartate aminotransferase/alanine aminotransferase levels in the hepatotoxicity group were 249/249 IU/L, respectively. Among the 17 patients with hepatotoxicity,12 showed anti–TB DIH. Ten patients showed PZA–related hepatotoxicity and 2 showed INH– or RMP–related hepatotoxicity. However, intergroup differences in the serum levels of the 4 anti–TB drugs were not statistically significant. Basal serum drug concentration was not associated with the risk anti–TB DIH in patients being treated with the currently recommended doses of first–line anti–TB treatment drugs.

Keywords :

Article: Download PDF    DOI : 10.36106/ijar  

Cite This Article:

A REVIEW ON HEPATOTOXICITY OF ANTITUBERCULOSIS THERAPY, Dr. Siddharth, G.Priyanka, Mirza Hassan INDIAN JOURNAL OF APPLIED RESEARCH : Volume-10 | Issue-3 | March-2020

Number of Downloads : 317

References :